Avidity biosciences to participate in upcoming investor conferences

La jolla, calif., feb. 11, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that the avidity management team will be participating at the following conferences: svb leerink 11th annual global healthcare conference moderated fireside chat february 18 th – 2:20pm et cowen 42nd annual health care conference corporate panel discussion: orphan neuro and neuromuscular – sarah boyce, ceo march 7 th, 2022 – 9:10am et needham 21st annual healthcare conference moderated fireside chat april 12, 2022 live webcasts of each event, up to date event details and an archived replay of the webcasts following each event, will be available on the "events and presentations" page in the "investors" section of avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
RNA Ratings Summary
RNA Quant Ranking